Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers
To avoid relying solely on serum prostate-specific antigen (sPSA) in screening for prostate cancer (PCa), we developed a scoring system for detecting PCa and the prediction of aggressiveness. We analyzed urine and plasma specimens from 121 patients with PCa or benign prostatic hyperplasia (BPH) for...
Gespeichert in:
| Veröffentlicht in: | Genetic testing and molecular biomarkers 2014-03, Vol.18 (3), p.156-163 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 163 |
|---|---|
| container_issue | 3 |
| container_start_page | 156 |
| container_title | Genetic testing and molecular biomarkers |
| container_volume | 18 |
| creator | Ma, Wanlong Diep, Kevin Fritsche, Herbert A Shore, Neal Albitar, Maher |
| description | To avoid relying solely on serum prostate-specific antigen (sPSA) in screening for prostate cancer (PCa), we developed a scoring system for detecting PCa and the prediction of aggressiveness. We analyzed urine and plasma specimens from 121 patients with PCa or benign prostatic hyperplasia (BPH) for the levels of UAP1, PDLIM5, IMPDH2, HSPD1, PCA3, PSA, TMPRSS2, ERG, GAPDH, and B2M genes. Patient age, sPSA level, and polymerase chain reaction data were entered through multiple algorithms to determine models most useful for the detection of cancer and predicting aggressiveness.
In the first algorithm, we distinguished PCa from BPH (area under the receiver operating characteristic curve [AUROC] of 0.78). Another algorithm distinguished patients with the Gleason score (GS) of ≥7 from GS of |
| doi_str_mv | 10.1089/gtmb.2013.0424 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1673396782</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1505254370</sourcerecordid><originalsourceid>FETCH-LOGICAL-c328t-426bf79bae42c95cfb3158b4ef895d8d863efac73bd96923f52c8135fcb316ee3</originalsourceid><addsrcrecordid>eNqFkDtPwzAQgC0EoqWwMqKMLCl-xx5ReUqVWGDFsp1zFcij2MnQf0-itqxMd6f77nT3IXRN8JJgpe82feOWFBO2xJzyEzQnmoscU1Gc_uVSzNBFSl8YS86UPEczygWhgrI5-nyo7KbtUl_5zLZlto3dsUy-i1W7ydIu9dBkoYtTN_W2h8zb1kPMhjQBw4jBfrq2qbGZq7rGxm-I6RKdBVsnuDrEBfp4enxfveTrt-fX1f0694yqPudUulBoZ4FTr4UPjhGhHIegtChVqSSDYH3BXKmlpiwI6hVhIvgRlABsgW73e8cLfwZIvWmq5KGubQvdkAyRBWNaFor-jwosqOCswCO63KN-_DtFCGYbq_GznSHYTPrNpN9M-s2kfxy4OeweXAPlH370zX4BjryCaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505254370</pqid></control><display><type>article</type><title>Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ma, Wanlong ; Diep, Kevin ; Fritsche, Herbert A ; Shore, Neal ; Albitar, Maher</creator><creatorcontrib>Ma, Wanlong ; Diep, Kevin ; Fritsche, Herbert A ; Shore, Neal ; Albitar, Maher</creatorcontrib><description>To avoid relying solely on serum prostate-specific antigen (sPSA) in screening for prostate cancer (PCa), we developed a scoring system for detecting PCa and the prediction of aggressiveness. We analyzed urine and plasma specimens from 121 patients with PCa or benign prostatic hyperplasia (BPH) for the levels of UAP1, PDLIM5, IMPDH2, HSPD1, PCA3, PSA, TMPRSS2, ERG, GAPDH, and B2M genes. Patient age, sPSA level, and polymerase chain reaction data were entered through multiple algorithms to determine models most useful for the detection of cancer and predicting aggressiveness.
In the first algorithm, we distinguished PCa from BPH (area under the receiver operating characteristic curve [AUROC] of 0.78). Another algorithm distinguished patients with the Gleason score (GS) of ≥7 from GS of <7 cancer or BPH (AUROC of 0.88). By incorporating the two algorithms into a scoring system, 75% of the analyzed samples showed concordance between the two models (99% specificity and 68% sensitivity for predicting GS ≥7 in this group).
A scoring system incorporating two algorithms using urine and plasma biomarkers highly predicts the presence of GS ≥7 PCa in 75% of patients. Our algorithms may assist with both biopsy indication and patient prognosis.</description><identifier>ISSN: 1945-0265</identifier><identifier>EISSN: 1945-0257</identifier><identifier>DOI: 10.1089/gtmb.2013.0424</identifier><identifier>PMID: 24512523</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aged, 80 and over ; Algorithms ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - urine ; Humans ; Male ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Staging - methods ; Prognosis ; Prostatic Hyperplasia - blood ; Prostatic Hyperplasia - diagnosis ; Prostatic Hyperplasia - pathology ; Prostatic Hyperplasia - urine ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - urine ; Research Design</subject><ispartof>Genetic testing and molecular biomarkers, 2014-03, Vol.18 (3), p.156-163</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c328t-426bf79bae42c95cfb3158b4ef895d8d863efac73bd96923f52c8135fcb316ee3</citedby><cites>FETCH-LOGICAL-c328t-426bf79bae42c95cfb3158b4ef895d8d863efac73bd96923f52c8135fcb316ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24512523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Wanlong</creatorcontrib><creatorcontrib>Diep, Kevin</creatorcontrib><creatorcontrib>Fritsche, Herbert A</creatorcontrib><creatorcontrib>Shore, Neal</creatorcontrib><creatorcontrib>Albitar, Maher</creatorcontrib><title>Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers</title><title>Genetic testing and molecular biomarkers</title><addtitle>Genet Test Mol Biomarkers</addtitle><description>To avoid relying solely on serum prostate-specific antigen (sPSA) in screening for prostate cancer (PCa), we developed a scoring system for detecting PCa and the prediction of aggressiveness. We analyzed urine and plasma specimens from 121 patients with PCa or benign prostatic hyperplasia (BPH) for the levels of UAP1, PDLIM5, IMPDH2, HSPD1, PCA3, PSA, TMPRSS2, ERG, GAPDH, and B2M genes. Patient age, sPSA level, and polymerase chain reaction data were entered through multiple algorithms to determine models most useful for the detection of cancer and predicting aggressiveness.
In the first algorithm, we distinguished PCa from BPH (area under the receiver operating characteristic curve [AUROC] of 0.78). Another algorithm distinguished patients with the Gleason score (GS) of ≥7 from GS of <7 cancer or BPH (AUROC of 0.88). By incorporating the two algorithms into a scoring system, 75% of the analyzed samples showed concordance between the two models (99% specificity and 68% sensitivity for predicting GS ≥7 in this group).
A scoring system incorporating two algorithms using urine and plasma biomarkers highly predicts the presence of GS ≥7 PCa in 75% of patients. Our algorithms may assist with both biopsy indication and patient prognosis.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Algorithms</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - urine</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging - methods</subject><subject>Prognosis</subject><subject>Prostatic Hyperplasia - blood</subject><subject>Prostatic Hyperplasia - diagnosis</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Prostatic Hyperplasia - urine</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - urine</subject><subject>Research Design</subject><issn>1945-0265</issn><issn>1945-0257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtPwzAQgC0EoqWwMqKMLCl-xx5ReUqVWGDFsp1zFcij2MnQf0-itqxMd6f77nT3IXRN8JJgpe82feOWFBO2xJzyEzQnmoscU1Gc_uVSzNBFSl8YS86UPEczygWhgrI5-nyo7KbtUl_5zLZlto3dsUy-i1W7ydIu9dBkoYtTN_W2h8zb1kPMhjQBw4jBfrq2qbGZq7rGxm-I6RKdBVsnuDrEBfp4enxfveTrt-fX1f0694yqPudUulBoZ4FTr4UPjhGhHIegtChVqSSDYH3BXKmlpiwI6hVhIvgRlABsgW73e8cLfwZIvWmq5KGubQvdkAyRBWNaFor-jwosqOCswCO63KN-_DtFCGYbq_GznSHYTPrNpN9M-s2kfxy4OeweXAPlH370zX4BjryCaQ</recordid><startdate>201403</startdate><enddate>201403</enddate><creator>Ma, Wanlong</creator><creator>Diep, Kevin</creator><creator>Fritsche, Herbert A</creator><creator>Shore, Neal</creator><creator>Albitar, Maher</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201403</creationdate><title>Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers</title><author>Ma, Wanlong ; Diep, Kevin ; Fritsche, Herbert A ; Shore, Neal ; Albitar, Maher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c328t-426bf79bae42c95cfb3158b4ef895d8d863efac73bd96923f52c8135fcb316ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Algorithms</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - urine</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging - methods</topic><topic>Prognosis</topic><topic>Prostatic Hyperplasia - blood</topic><topic>Prostatic Hyperplasia - diagnosis</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Prostatic Hyperplasia - urine</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - urine</topic><topic>Research Design</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Wanlong</creatorcontrib><creatorcontrib>Diep, Kevin</creatorcontrib><creatorcontrib>Fritsche, Herbert A</creatorcontrib><creatorcontrib>Shore, Neal</creatorcontrib><creatorcontrib>Albitar, Maher</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Genetic testing and molecular biomarkers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Wanlong</au><au>Diep, Kevin</au><au>Fritsche, Herbert A</au><au>Shore, Neal</au><au>Albitar, Maher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers</atitle><jtitle>Genetic testing and molecular biomarkers</jtitle><addtitle>Genet Test Mol Biomarkers</addtitle><date>2014-03</date><risdate>2014</risdate><volume>18</volume><issue>3</issue><spage>156</spage><epage>163</epage><pages>156-163</pages><issn>1945-0265</issn><eissn>1945-0257</eissn><abstract>To avoid relying solely on serum prostate-specific antigen (sPSA) in screening for prostate cancer (PCa), we developed a scoring system for detecting PCa and the prediction of aggressiveness. We analyzed urine and plasma specimens from 121 patients with PCa or benign prostatic hyperplasia (BPH) for the levels of UAP1, PDLIM5, IMPDH2, HSPD1, PCA3, PSA, TMPRSS2, ERG, GAPDH, and B2M genes. Patient age, sPSA level, and polymerase chain reaction data were entered through multiple algorithms to determine models most useful for the detection of cancer and predicting aggressiveness.
In the first algorithm, we distinguished PCa from BPH (area under the receiver operating characteristic curve [AUROC] of 0.78). Another algorithm distinguished patients with the Gleason score (GS) of ≥7 from GS of <7 cancer or BPH (AUROC of 0.88). By incorporating the two algorithms into a scoring system, 75% of the analyzed samples showed concordance between the two models (99% specificity and 68% sensitivity for predicting GS ≥7 in this group).
A scoring system incorporating two algorithms using urine and plasma biomarkers highly predicts the presence of GS ≥7 PCa in 75% of patients. Our algorithms may assist with both biopsy indication and patient prognosis.</abstract><cop>United States</cop><pmid>24512523</pmid><doi>10.1089/gtmb.2013.0424</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1945-0265 |
| ispartof | Genetic testing and molecular biomarkers, 2014-03, Vol.18 (3), p.156-163 |
| issn | 1945-0265 1945-0257 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1673396782 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Algorithms Biomarkers, Tumor - blood Biomarkers, Tumor - urine Humans Male Middle Aged Neoplasm Invasiveness Neoplasm Staging - methods Prognosis Prostatic Hyperplasia - blood Prostatic Hyperplasia - diagnosis Prostatic Hyperplasia - pathology Prostatic Hyperplasia - urine Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - pathology Prostatic Neoplasms - urine Research Design |
| title | Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T12%3A47%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20and%20prognostic%20scoring%20system%20for%20prostate%20cancer%20using%20urine%20and%20plasma%20biomarkers&rft.jtitle=Genetic%20testing%20and%20molecular%20biomarkers&rft.au=Ma,%20Wanlong&rft.date=2014-03&rft.volume=18&rft.issue=3&rft.spage=156&rft.epage=163&rft.pages=156-163&rft.issn=1945-0265&rft.eissn=1945-0257&rft_id=info:doi/10.1089/gtmb.2013.0424&rft_dat=%3Cproquest_cross%3E1505254370%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505254370&rft_id=info:pmid/24512523&rfr_iscdi=true |